6-乙基-2-甲基-1,3-苯并噻唑 | 18879-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 6-乙基-2-甲基-1,3-苯并噻唑
• 英文名称: 6-ethyl-2-methyl-benzothiazole
• 英文别名: 6-Aethyl-2-methyl-benzothiazol；Benzothiazole, 6-ethyl-2-methyl-；6-ethyl-2-methyl-1,3-benzothiazole
• CAS: 18879-32-8
• 化学式: C₁₀H₁₁NS
• mdl: MFCD11217461
• 分子量: 177.27
• InChiKey: HKMHIFQWLMRSBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  N-(4-ethylphenyl)acetamide 在 sodium sulfide 、 tetraphosphorus decasulfide 、 xylene 、 potassium hexacyanoferrate(III) 作用下， 生成 6-乙基-2-甲基-1,3-苯并噻唑
  参考文献：
  名称：

  Metzger; Plank, Bulletin de la Societe Chimique de France, 1956, p. 684,688

  摘要：

  DOI：

文献信息

• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Cook, II James H.

  公开号：US20090270405A1

  公开（公告）日：2009-10-29

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱性α7受体的配体，可能对治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病，有用。
• Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070072898A1

  公开（公告）日：2007-03-29

  A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.

  由式(I)表示的吡唑并[1,5-a]吡啶衍生物及其盐表现出优异的MAPKAP-K2抑制活性。因此，包含该化合物作为活性成分的药物预计对治疗或预防由MAPKAP-K2介导的疾病，如炎症损伤、自身免疫疾病、asteropathia destruens、癌症和/或肿瘤生长具有重要价值。
• Luciferin Derivatives from Bicyclic Reactants and Aminothiol Derivatives and Methods of Use Thereof
  申请人：The Regents of the University of California

  公开号：US20130287699A1

  公开（公告）日：2013-10-31

  The present disclosure features a condensation reaction and a luciferin-unmasking reaction that can be carried out under physiological conditions. In general, the condensation reaction involves reacting a bicyclic reactant with an aminothiol derivative, generating a luciferin or luciferin derivative. A luciferin can provide detectable luminescence. A luciferin derivative can be unmasked to provide detectable luminescence in a luciferin-unmasking reaction. The present disclosure provides bicyclic reactants and aminothiol derivatives suitable for use in the condensation reaction. The condensation and luciferin-unmasking reactions find use in a variety of applications, which are also provided.

  本公开涉及一种可以在生理条件下进行的缩合反应和发光素暴露反应。通常，缩合反应涉及将双环反应物与氨基硫醇衍生物反应，生成发光素或发光素衍生物。发光素可以提供可检测的发光。发光素衍生物可以在发光素暴露反应中被揭示出来，提供可检测的发光。本公开提供适用于缩合反应的双环反应物和氨基硫醇衍生物。缩合和发光素暴露反应在各种应用中有用，这些应用也被提供。
• Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof
  申请人：UNOKI Gen

  公开号：US20090054472A1

  公开（公告）日：2009-02-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  式（1）所表示的吡唑并嘧啶衍生物及其药学上可接受的盐，表现出对MAPKAP-K2的优异抑制活性。因此，含有该化合物作为活性成分的药物预计将对由MAPKAP-K2介导的疾病具有治疗作用，例如，炎症性疾病、自身免疫性疾病、破坏性骨病、癌症和/或肿瘤生长。